HekeTiss SA is a biotechnology company developing regenerative cell therapies to restore skin function and promote tissue repair. The company’s lead program targets chronic wounds, a major unmet medical need.

Founded in 2022 as a spin-off from the University of Geneva and the Geneva University Hospitals, HekeTiss builds on pioneering research in regenerative medicine and immunology.

Headquartered in Plan-les-Ouates in the canton of Geneva and hosted at the innovation incubator Fondation Genevoise pour l’Innovation Technologique (FONGIT), HekeTiss has developed a patented stem cell technology for skin repair. Its lead product candidate, TrophiPatch, is an off-the shelf allogeneic adipose-derived stem cell-based skin patch currently being evaluated in clinical studies for the treatment of chronic wounds.

The company has received multiple innovation awards and competitive grants and obtained the Innosuisse Certification for Readiness for Sustainable Growth in 2024. In 2025, HekeTiss was ranked 12th among biotechnology companies in the TOP100 Swiss startups.

HekeTiss aims to become a leading innovator in regenerative cell therapies that restore skin function and enable next-generation approaches to skin regeneration.